Uterine Artery Embolization Compared with Uterine Artery Embolization/Methotrexate Plus Curettage in the Conservative Treatment for Patient with Cesarean Scar Pregnancy

X. Tao,P.T. Ramirez,Y. Zhu,J-M. Yamal,G.F. Pratt,L. Yin
DOI: https://doi.org/10.1016/j.jmig.2010.08.254
IF: 4.314
2010-01-01
Journal of Minimally Invasive Gynecology
Abstract:Study Objective: The purpose of this retrospective study was to compare the safety, efficacy, cost and side effects of uterine artery embolization (UAE) plus curettage with UAE/methotrexate plus curettage in the management of patients with cesarean scar pregnancy (CSP). Design: Retrospective study. Setting: University hospital. Patients: Patients with cesarean scar pregnancy. Intervention: We retrospectively reviewed outcomes for patients with CSP underwent UAE with or without methotrexate followed by curettage at Peking University First Hospital between 2003 and 2008. Patients were study eligible if they had CSP diagnosed by transvaginal color Doppler sonography (TV-CDS) and were treated with UAE with or without methotrexate, followed by curettage. Measurements and Main Results: We identified 31 eligible patients. Among 31 patients, 18 patients were treated with UAE plus curettage; 13 patients underwent UAE/methotrexate plus curettage. At the time of diagnosis, gestational age tended to be bigger for the UAE/methotrexate group than UAE group (median 9.3 weeks vs 7.3 weeks, p=0.08). The size of conceptus mass measured through TV-CDS was significantly larger in the UAE/methotrexate group than in the UAE group (median 6.0cm vs 3.65cm, p=0.002). The β-human chorionic gonadotropin (β-HCG) normalization tended to be longer in the UAE+MTX group (p=0.06). No severe side effects were observed in related with UAE and/or methotrexate. No patient underwent a hysterectomy as a result of CSP. Of the 17 patients with available follow-up information (median follow-up time, 20 months), all patients resumed normal menstruation and one patients had two times of unwanted normal pregnancy and underwent vacuum abortion uneventfully. Conclusion: UAE with or without methotrexate plus curettage is safe, effective, and fertility-preserving treatment option for patients with CSP. UAE/methotrexate tends to be used in patients with larger gestational age and bigger conceptus mass.
What problem does this paper attempt to address?